Table 3.

Tumor Doubling Rates in Patients Who Underwent Active Surveillance Pre- and Post-PE-V Stratified Based on Patient Age at Time of Presentation

			Tumor doubling rate (per year)
		No. of patients	>0.5, n (%)	0.1–0.5, n (%)	−0.1 to 0.1, n (%)	<−0.1, n (%)
Pre-PE-V	<40 Years	39	13 (33.3)	21 (53.8)	4 (10.3)	1 (2.6)
Post-PE-V	<40 Years	54	2 (3.7)	10 (18.5)	27 (50.0)	15 (27.8)
Pre-PE-V	40–59 Years	83	34 (41.0)	43 (51.8)	6 (7.2)	0
Post-PE-V	40–59 Years	111	5 (4.6)	15 (13.5)	52 (46.8)	39 (35.1)
Pre-PE-V	≥60 Years	75	30 (40.0)	35 (46.7)	10 (13.3)	0
Post-PE-V	≥60 Years	126	4 (3.2)	10 (7.9)	61 (48.4)	51 (40.5)

Results of statistical analysis for pre-PE-V versus post-PE-V: p < 0.001 (≤40 years), p < 0.001 (41–59 years), p < 0.001 (≥60 years). Pre: p = 0.416 (≤40 years vs. 41–59 years), p = 0.644 (41–59 years vs. ≥60 years). Post: p = 0.722 (≤40 years vs. 41–59 years), p = 0.615 (41–59 years vs. ≥60 years).